Day: November 21, 2022
– Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica’s pipeline of first-in-class product candidates for life-threatening inflammatory diseases
– Combined company is expected to be funded with cash and cash equivalents of approximately $35 million at closing, with an expected runway into the second half of 2024
– Phase 2b results in acute pancreatitis for lead product candidate Auxora expected in second half of 2023
– Companies will host joint webcast on November 22, 2022, at 8:00 a.m. Eastern Time
REDWOOD CITY, Calif. and LA JOLLA, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) — Graybug Vision, Inc. (Nasdaq: GRAY) (Graybug) and CalciMedica Inc. (CalciMedica) today announced that they have entered into a definitive merger agreement to combine the companies in an all-stock transaction....
InspireSemi Reports Third Quarter 2022 Financial Results and Provides Business Update
Written by Customer Service on . Posted in Public Companies.
Company to Host Conference Call November 22, 2022 at 10:00 am ET
VANCOUVER, British Columbia and AUSTIN, Texas, Nov. 21, 2022 (GLOBE NEWSWIRE) — Inspire Semiconductor Holdings Inc. (TSXV: INSP) (“InspireSemi” or the “Company”), a chip design company that has built a technology foundation to deliver revolutionary performance, today announced financial results for the third quarter ended September 30, 2022 and provided a business update. All financial information is presented in United States (“US”) Dollars unless otherwise indicated.
“In the third quarter, we made substantial progress executing on our plan to become a game-changer in the accelerated computing solution industry,” said Ron Van Dell, CEO of InspireSemi. “We are in the final development stages of our anxiously awaited next-generation Thunderbird compute accelerator,...
Aridis Pharmaceuticals Announces Third Quarter 2022 Financial Results and Business Update
Written by Customer Service on . Posted in Public Companies.
Top-line data from the Phase 3 clinical trial evaluating AR-301 for the treatment of VAP expected in December of this year
LOS GATOS, Calif., Nov. 21, 2022 (GLOBE NEWSWIRE) — Aridis Pharmaceuticals, Inc. (Nasdaq: ARDS), a biopharmaceutical company focused on the discovery and development of novel anti-infective therapies for treating life-threatening infections, today reported financial and corporate results for its third quarter ended September 30, 2022.
Third Quarter HighlightsClosed enrollment in the Company’s Phase 3 study evaluating AR-301 for the treatment of Ventilator Associated Pneumonia (VAP). Aridis expects to report top-line data from this study in December 2022.
Continued enrollment in the Company’s Phase 2a study of AR-501 targeting cystic fibrosis (CF), conducted in collaboration with funding support from the Cystic...
ArrowMark Financial Corp. Releases Month End Estimated Net Asset Value as of October 2022
Written by Customer Service on . Posted in Public Companies.
Agora, Inc. Reports Third Quarter 2022 Financial Results
Written by Customer Service on . Posted in Public Companies.
Tenaya Therapeutics Announces Closing of Public Offering
Written by Customer Service on . Posted in Public Companies.
Yamana Provides Notice of Record and Meeting Dates for the Proposed Transaction With Agnico and Pan American Silver and Declares Fourth Quarter Dividend
Written by Customer Service on . Posted in Public Companies.
TORONTO, Nov. 21, 2022 (GLOBE NEWSWIRE) — YAMANA GOLD INC. (TSX: YRI, NYSE: AUY, LSE: AUY) (“Yamana” or the “Company”) announces that it has filed the required notice setting the record and meeting dates in respect of the special meeting of shareholders to consider the previously announced proposed transaction (the “Proposed Transaction”) with Agnico Eagle Mines Limited and Pan American Silver Corp. (“Pan American Silver”). The record date, which is the date of record for determination of shareholders entitled to receive notice of and vote at the special meeting of shareholders, is set as December 14, 2022 and the special meeting of shareholders will be convened on January 31, 2023. Yamana has been advised that a Pan American Silver shareholder meeting is scheduled for the same day as the Company’s special meeting of shareholders.
Further...
Fanhua Reports Third Quarter 2022 Unaudited Financial Results
Written by Customer Service on . Posted in Public Companies.
— Operating Income for the Third Quarter of 2022 Grew 14.2% YOY —
GUANGZHOU, China, Nov. 21, 2022 (GLOBE NEWSWIRE) — Fanhua Inc. (Nasdaq: FANH) (the “Company” or “Fanhua”), a leading independent financial services provider in China, today announced its unaudited financial results for the third quarter ended September 30, 20221.
Financial Highlights for the Third Quarter of 2022(In thousands, except per ADS data)
2021Q3(RMB)
2022Q3(RMB)
2022Q3(US$)
Change %Total net revenues
683,537
624,746
87,825
(8.6
)Operating income
28,163
32,165
4,522
14.2
Net income attributable to the Company’s shareholders
34,250
35,371
4,972
3.3
Diluted net income per ADS
0.64
0.66
0.09
3.1
Cash, cash equivalents and short-term investments and others (as of September 30, 2021 and 2022)
1,397,727
1,296,9262
182,319
(7.2
)Mr....